AG真人官方

Borr Drilling Limited (BORR) has launched a preliminarily marketed public offering of 50 million common shares via a two-step settlement structure. Approximately 30 million shares are expected to settle on 7 July 2025 (the 鈥淔irst Settlement鈥�) while the remaining 20 million will settle on or about 7 August 2025 (the 鈥淪econd Settlement鈥�) only if shareholders approve an increase in authorised share capital at a Special General Meeting (SGM) on 6 August 2025. The shares are listed on the NYSE; the last reported price on 1 July 2025 was $1.95.

Net proceeds鈥攚hose exact amount will depend on final pricing鈥攁re earmarked for general corporate purposes such as debt service, capital expenditure and working-capital needs. The equity raise is also a condition precedent for agreed amendments to Borr鈥檚 financing package: commitments have been received to lift the Super Senior Revolving Credit Facility to $200 million (+$50 million), re-classify the $45 million guarantee line, and add a new $34 million senior secured RCF, jointly raising available liquidity by more than $100 million and easing covenant thresholds (lower liquidity minimum, higher leverage ceiling, lower coverage ratios).

Operationally, Borr has booked 13 new contract awards/LOIs/LOAs in 2025, adding ~3,010 potential rig-days and $366 million of revenue backlog (average day-rate $121k). Contract coverage now stands at 84% for 2025 and 45% for 2026 at average day-rates of $144k and $141k, respectively.

Leadership refresh: CCO Bruno Morand will become CEO on 1 September 2025; current CEO Patrick Schorn will transition to Executive Chair, while Chairman Tor Olav Tr酶im will remain on the board. Investor Granular Capital鈥檚 CIO, Thiago Mordehachvili, is nominated to join the board, contingent on SGM approval to expand board size.

Several insiders鈥擲chorn ($1 m), Morand ($0.3 m) and Drew Holding Ltd. ($10 m)鈥攊ntend to subscribe, all electing to receive shares in the Second Settlement. If the SGM fails, only the First Settlement closes, leaving the remaining 20 million shares undelivered.

Salesforce, Inc. (CRM) has filed a Form 144 signaling the intended sale of 144,000 common shares through Merrill Lynch on the NYSE around 01 July 2025. At the reference price used in the filing, the transaction is valued at approximately $39.24 million. The seller鈥攚hose name and relationship to Salesforce are not disclosed鈥攐riginally obtained the shares on 22 March 2019 via the exercise of a stock option and paid for them in cash on 22 March 2023. No additional Salesforce shares have been sold by this filer during the past three months. The proposed sale represents roughly 0.015 % of the company鈥檚 956 million shares outstanding, suggesting minimal impact on overall float or control. The filing contains no indication of a Rule 10b5-1 trading plan, nor any remarks beyond the standard certification language.

ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and 伪-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).

At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of 鈮�30%鈥攖he study鈥檚 threshold for overall response鈥攐ccurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded 鈮�30% tumor reduction, underscoring central-nervous-system activity.

Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.

Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed 鈥渇iled鈥� for Exchange Act purposes.

ArriVent BioPharma (NASDAQ:AVBP) submitted a routine Form 4 on 28 June 2025 reporting an insider transaction by director Merdad Parsey.

According to the filing, Parsey acquired 15,502 non-qualified stock options on 18 June 2025 at an exercise price of $24.89 per share. The options become exercisable on 18 June 2026 and expire on 17 June 2035. No common shares were sold or purchased outright, and the transaction was reported as direct ownership. After the grant, Parsey holds an additional 15,502 derivative securities linked to AVBP common stock.

No other material changes, sales, or new share ownership percentages were disclosed in this filing.

Form 4 filing reveals that Kristine Peterson, Director at ArriVent BioPharma, was granted 15,502 non-qualified stock options on June 18, 2025. The options have the following key terms:

• Exercise price set at $24.89 per share
• Exercisable starting June 18, 2026
• Expiration date of June 17, 2035
• Underlying security is ArriVent BioPharma common stock

The options were acquired at a price of $0.00, indicating a compensation grant. The filing was signed by James Kastenmayer as attorney-in-fact for Peterson on June 20, 2025. This equity compensation aligns the director's interests with shareholders through long-term stock ownership potential.

ArriVent BioPharma director John Hohneker received a non-qualified stock option grant on June 18, 2025. The key details of this insider transaction include:

• Granted 15,502 stock options to purchase common stock
• Exercise price set at $24.89 per share
• Options become exercisable on June 18, 2026
• Options expire on June 17, 2035
• Total cost basis of $0.00 as this was a compensation grant

The transaction was reported via Form 4 filing and executed through attorney-in-fact James Kastenmayer. This equity-based compensation aligns the director's interests with shareholders and represents a standard component of non-employee director compensation.

ArriVent BioPharma director Chris Nolet received a new stock option grant on June 18, 2025. The transaction details include:

• Granted 15,502 non-qualified stock options to purchase common stock
• Exercise price set at $24.89 per share
• Options become exercisable on June 18, 2026
• Options expire on June 17, 2035
• Zero cost basis for the options grant

This Form 4 filing, signed by James Kastenmayer as attorney-in-fact, represents a standard director compensation equity grant. The options provide Nolet with long-term alignment with shareholder interests through a 10-year exercise window, subject to a one-year vesting requirement.

On June 18, 2025, ArriVent BioPharma, Inc. (Nasdaq: AVBP) convened its 2025 Annual Meeting of Stockholders via live audio webcast. A quorum of 25,159,248 shares (73.89% of the 34,045,193 shares outstanding) was represented.

Key agenda items and results:

• Election of Class I Directors (terms expiring 2028)
  鈥� Zhengbin (Bing) Yao, Ph.D.: 22,116,332 for / 442,833 withheld / 2,600,083 broker non-votes
  鈥� Kristine Peterson: 21,932,842 for / 626,323 withheld / 2,600,083 broker non-votes
• Auditor Ratification
  PricewaterhouseCoopers LLP re-appointed for the fiscal year ending December 31, 2025 with 24,991,469 for, 242 against and 167,537 abstentions (0 broker non-votes).

No other business was brought before the meeting. The results indicate broad shareholder support for existing governance and the continued engagement of a Big-4 audit firm. No financial guidance, operational updates or strategic transactions were disclosed in this Form 8-K.